Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "2023"

1144 News Found

Ayu Health acquires SwasthyaSewak Hospitals in Jaipur
Startup | February 16, 2022

Ayu Health acquires SwasthyaSewak Hospitals in Jaipur

Through this acquisition, Ayu Health will add 1000 beds to provide localised primary and tertiary medical care for citizens of Jaipur


USFDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences
Drug Approval | February 10, 2022

USFDA awards QIDP designation for prevention of chlamydia to Evofem Biosciences

Adds five years of market exclusivity on approval


Piramal Pharma Solutions plans expansion in Scotland
News | February 09, 2022

Piramal Pharma Solutions plans expansion in Scotland

In the first phase of the Grangemouth site expansion, two new ADC manufacturing suites, operational by Q3 2023, will be added to the existing three


Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct
News | February 07, 2022

Caplin Point’s Q3 in line; outlook positive amid expansion plans: ICICI Direct

Key takeaways of recent quarter & conference call highlights


Budget 22-23: Healthcare sector applauds focus on mental health
News | February 01, 2022

Budget 22-23: Healthcare sector applauds focus on mental health

A National Tele Mental Health Programme is being launched to address mental health issues. We spoke to healthcare industry leaders who shared their outlook


Lannett receives USFDA safety review for biosimilar insulin glargine
Biotech | January 22, 2022

Lannett receives USFDA safety review for biosimilar insulin glargine

Go-ahead for pivotal clinical trial which is expected to commence by March


Max Healthcare to add over 300 beds in NCR ties up with Muthoot Hospitals
Hospitals | January 20, 2022

Max Healthcare to add over 300 beds in NCR ties up with Muthoot Hospitals

The hospital will be operated under the name and style of Max Super Speciality Hospital, Dwarka


We achieved  40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
Interviews | January 11, 2022

We achieved 40% revenue growth in 2021 : Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & Director & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals
interviews | January 10, 2022

We achieved 40% revenue growth in 2021: Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals

The biopharmaceutical market has been on a growth curve. India is number three in the Asia Pacific market. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals shares a perspective on the industry


Domestic and emerging markets will drive pharma growth: ICRA
News | January 04, 2022

Domestic and emerging markets will drive pharma growth: ICRA

Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters